Source: Clinical Laboratory News
Startup life sciences firm ThermaGenix has exclusively licensed technologies from Brandeis University that are designed to enhance detection and analysis of DNA and RNA via polymerase chain reaction (PCR). ThermaGenix was founded in 2014 by Lawrence Wangh, PhD, professor of biology, reproduction biology, and molecular cytology at Brandeis in Waltham, Massachusetts. The company has now obtained broad rights to PCR solutions developed by Wangh and colleagues, including ThermaStop and ThermaGo, which ThermaGenix will sell starting in May of this year. ThermaGenix also plans to use additional methods and reagents licensed from Brandeis to construct molecular liquid biopsies, as well as molecular assays for microbial species identification. These reagents are designed to eliminate all forms of mispriming before, during, and after PCR and reverse transcription PCR amplification, with the aim of increasing assay quality, quantitative accuracy, sensitivity, and multiplexing capabilities.